image credit- shutterstock
A new collaboration between Texas Medical Center, the world’s largest innovation hub, and the Osong Medical Innovation Foundation (KBIOHealth), South Korea’s leading national medical initiative, is set to accelerate the market entry and commercialisation of Korean startups in the United States through the TMC | Republic of Korea BioBridge.
Under a new Memorandum of Understanding, both organisations will create gateway opportunities for entrepreneurs, researchers, clinicians, and industry partners. The partnership will also foster clinical research and facilitate collaborative projects and policy dialogues to advance innovation and commercialization across public, private and academic sectors.
“Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally,” said William McKeon, president and CEO of the Texas Medical Center.
As part of the Republic of Korea BioBridge agreement, the Texas Medical Center will offer a customised programme designed to serve as a strategic gateway for international healthcare companies preparing to enter the US market. This Global Innovators Launch Pad begins with a competitive application process, through which selected startup founders participate in a 10-week residency at the TMC Innovation Factory in Houston.
Throughout the programme, entrepreneurs receive targeted support in essential areas for US market success, including building foundational infrastructure, validating clinical approaches, and securing critical funding—accelerating their journey from innovation to impact.
“By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide,” said Myoung Su Lee, Chairman, KBIOHealth.
